Bio & Insurance Information

Dr. Uzair Chaudhary graduated from the Aga Khan Medical College and completed his residency program at the Indiana University School of Medicine. Then, he did a fellowship at the UCSF . Dr. Chaudhary is specialized in Hematology and board certified in Hematology and Medical Oncology. He has been in practice for more than 20 years and is affiliated with the Saint Agnes Medical Center, UCSF Medical Center, Fresno Heart and Surgical Hospital, and Community Regional Medical Center. During his career, he has also contributed to several clinical research publications.



Education & Training

Aga Khan Medical College

Medical School

Indiana University School of Medicine

Residency

UCSF

Fellowship

Board Certifications

American Board of Internal Medicine - Hematology

American Board of Internal Medicine - Oncology

Hospitals & Clinics

Community Regional Medical Center

Languages: English/Spanish

(559) 459-6000

2823 Fresno St

Fresno, California 93721

Read More

Fresno Heart & Surgical Hospital

Languages: English/Spanish

(559) 433-8000

15 E. Audubon Drive

Fresno, California 93720

Read More

Saint Agnes Medical Center

Languages: English/Spanish

(559) 450-3000

1303 E Herndon Ave

Fresno, California 93720

Read More

UCSF Medical Center

Languages: English/Spanish

(415) 353-1037

505 Parnassus Ave

San Francisco, California 94143

Read More

Publications

Dr. Uzair Chaudhary has contributed to 3 publications.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or un...

Esnaola, N. F.,Chaudhary, U. B.,O'Brien, P.,Garrett-Mayer, E.,Camp, E. R.,Thomas, M. B.,Cole, D. J.,Montero, A. J.,Hoffman, B. J.,Romagnuolo, J.,Orwat, K. P.,Marshall,...; Int. J. Radiat. Oncol. Biol. Phys.. 2014 Mar 13.

See more >>

Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review.

Sio, T. T.,Ko, J.,Gudena, V. K.,Verma, N.,Chaudhary, U. B.; Int. J. Urol.. 2014 Jan 25.

See more >>

Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma.

Marshall, D. T.,Ramey, S.,Golshayan, A. R.,E Keane, T.,Kraft, A. S.,Chaudhary, U.; Clin Genitourin Cancer. 2014 Jan 01.

See more >>